- Home
- DAWN vs TERN Comparison
DAWN vs TERN Comparison
Compare DAWN & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- TERN
- Stock Information
- Founded
- DAWN 2018
- TERN 2017
- Country
- DAWN United States
- TERN United States
- Employees
- DAWN N/A
- TERN N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- TERN Health Care
- Exchange
- DAWN Nasdaq
- TERN Nasdaq
- Market Cap
- DAWN 624.8M
- TERN 634.5M
- IPO Year
- DAWN 2021
- TERN 2021
- Fundamental
- Price
- DAWN $7.15
- TERN $7.21
- Analyst Decision
- DAWN Strong Buy
- TERN Buy
- Analyst Count
- DAWN 7
- TERN 6
- Target Price
- DAWN $27.86
- TERN $13.99
- AVG Volume (30 Days)
- DAWN 1.1M
- TERN 1.2M
- Earning Date
- DAWN 10-29-2025
- TERN 11-11-2025
- Dividend Yield
- DAWN N/A
- TERN N/A
- EPS Growth
- DAWN N/A
- TERN N/A
- EPS
- DAWN N/A
- TERN N/A
- Revenue
- DAWN $187,638,000.00
- TERN N/A
- Revenue This Year
- DAWN $12.56
- TERN N/A
- Revenue Next Year
- DAWN $48.02
- TERN N/A
- P/E Ratio
- DAWN N/A
- TERN N/A
- Revenue Growth
- DAWN 2190.50
- TERN N/A
- 52 Week Low
- DAWN $5.64
- TERN $1.87
- 52 Week High
- DAWN $16.76
- TERN $11.00
- Technical
- Relative Strength Index (RSI)
- DAWN 51.15
- TERN 56.10
- Support Level
- DAWN $7.03
- TERN $6.78
- Resistance Level
- DAWN $7.58
- TERN $7.67
- Average True Range (ATR)
- DAWN 0.27
- TERN 0.43
- MACD
- DAWN -0.04
- TERN -0.05
- Stochastic Oscillator
- DAWN 29.55
- TERN 45.37
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.